Innovus Pharma Receives Approval from Health Canada for its UriVarx™ Product for the Indication to Reduce
Symptoms of Overactive Bladder such as Daytime Urinary Frequency, Urgency and Nocturia
UriVarx™ is the Fourth Innovus Pharma Product to be Approved by Health Canada
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage
pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today
announced that it has received approval from Health Canada to add its clinically proven UriVarx™ product as a Natural Health
Product (“NHP”) with the indication to Reduce Symptoms of Overactive Bladder (“OAB”) such as Daytime Urinary Frequency, Urgency and
Nocturia.
“OAB is a serious medical condition that affects millions of Canadians each year. However, the medications currently available
may cause significant side effects, leading many patients to stop treatment. That’s why Innovus Pharma is so pleased to offer this
new natural treatment option,” said Dr. Bassam Damaj, the President and Chief Executive Officer of the Company.
In addition to four approved products in Canada, Innovus Pharma has filed for approval for two more of its products, namely
Vesele® and AllerVarx™, and is expected to file for at least two additional product approvals in that country before the end of the
year.
“With our growing approved pipeline of products and our current three commercialized products in Canada, we are assessing the
launch of our Beyond Human® sales and marketing platform in Canada to boost the sales of our products there,” Dr. Damaj
continued.
About UriVarx™
UriVarx™ is clinically proven to reduce urinary urgency, accidents and both day and night frequency in OAB and Urinary
Incontinence (“UI”) patients.
UriVarx™ has undergone two double blind and comparative trials in both male and female OAB and UI patients. The clinical results
include:
- Reduction of ~56% in Urge Incontinence;
- Reduction of ~66% in Stress Incontinence;
- Reduction of ~61% in Urinary Urgency;
- Reduction of ~33% in Urinary Frequency meaning the total average urinary frequency was in the
normal/ideal range after two months of use; and
- Reduction of ~46% in Nocturia.
According to the Canadian Continence Foundation (the “Foundation”), OAB is a medical term that describes various symptoms caused
by involuntary bladder spasms, including urinary frequency, especially at night, and urgency with or without involuntary leakage.
These symptoms may occur without obvious cause or be secondary to certain diseases of the nervous system. The Foundation estimates
that nearly 1 in 5 Canadians over the age of 35 suffers from overactive bladder. The condition, with frequency and urgency only,
affects men and women of all ages, although most are under age 65.*
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve
men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial
partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our
on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing
prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com ; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com .
*The Canadian Continence Foundation: http://www.canadiancontinence.ca/EN/types-of-urinary-incontinence.php.
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information
contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties
that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, projected revenues from the UriVarx™ product in Canada if approved in that country,
estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and
staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could
differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the
Company’s most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
Emerging Markets Consulting, LLC
James S. Painter III
407-340-0226
jamespainter@emergingmarketsllc.com
or
Chesapeake Group
410-825-3930
info@chesapeakegp.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170906005637/en/